Secondary Cancer Risk After Radiation Therapy for Rectal Cancer
NCT ID: NCT02572362
Last Updated: 2016-12-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
25 participants
OBSERVATIONAL
2015-08-31
2016-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Radiation Dose Escalation in Locally Advanced Rectal Cancer
NCT02603302
Preoperative Chemo-radiation With IG-IMRT Dose Escalation for Locally Advanced Rectal Cancers
NCT03200249
Concurrent Chemoradiation With Concomitant Boost In Locally Advanced Rectal Cancer
NCT02723253
Palliative Short-Course Radiotherapy in Rectal Cancer
NCT02639403
Planned Non-operative Management for Rectal Cancer
NCT05241574
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
No intervention in this retrospective study
No Intervention in this retrospective Analysis. All patients included did receive Radiation therapy Independent of this study
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* pre or postoperative radiation therapy for rectal cancer
* Planning CT
Exclusion Criteria
18 Years
100 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Klinik Hirslanden, Zurich
OTHER
Kantonsspital Graubuenden
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Daniel Rudolf Zwahlen
MD, MBA
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Daniel R Zwahlen, MD, MBA
Role: PRINCIPAL_INVESTIGATOR
Kantonsspital Graubuenden
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Klinik Hirslanden, Institute for Radiotherapy
Zurich, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Zwahlen DR, Bischoff LI, Gruber G, Sumila M, Schneider U. Estimation of second cancer risk after radiotherapy for rectal cancer: comparison of 3D conformal radiotherapy and volumetric modulated arc therapy using different high dose fractionation schemes. Radiat Oncol. 2016 Nov 10;11(1):149. doi: 10.1186/s13014-016-0723-6.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KEK-ZH-Nr. 2014-0255
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.